Kinner M, Prehn C, Schneider R, et al. - Since a side‐effect of natalizumab (NTZ) treatment for relapsing remitting multiple sclerosis (MS) is progressive multifocal leukoencephalopathy (PML) which potentially results in a substantial increase of physical as well as mental disability, therefore, researchers assessed neuropsychological disease course of NTZ‐PML patients. They also compared NTZ‐PML patients with two different non‐PML MS cohorts, focusing on neuropsychological deficits. A worse performance in neuropsychological examinations was evident in all stages of disease, predominantly impacting visuo‐spatial abilitiy and working memory, among NTZ‐PML patients vs controls. Findings of even long‐term‐follow‐up of NTZ‐PML patients revealed working‐memory and visuospatial ability as the core neuropsychological deficits in this patient population. These observations should be taken into account in neurorehabilitation strategies.